GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Equity-to-Asset

Elicera Therapeutics AB (OSTO:ELIC) Equity-to-Asset : 0.38 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Elicera Therapeutics AB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was kr11.40 Mil. Elicera Therapeutics AB's Total Assets for the quarter that ended in Dec. 2023 was kr30.18 Mil.

The historical rank and industry rank for Elicera Therapeutics AB's Equity-to-Asset or its related term are showing as below:

OSTO:ELIC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38   Med: 0.81   Max: 0.99
Current: 0.38

During the past 5 years, the highest Equity to Asset Ratio of Elicera Therapeutics AB was 0.99. The lowest was 0.38. And the median was 0.81.

OSTO:ELIC's Equity-to-Asset is ranked worse than
72.23% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs OSTO:ELIC: 0.38

Elicera Therapeutics AB Equity-to-Asset Historical Data

The historical data trend for Elicera Therapeutics AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB Equity-to-Asset Chart

Elicera Therapeutics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
0.99 0.81 0.95 0.71 0.38

Elicera Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.70 0.64 0.75 0.38

Competitive Comparison of Elicera Therapeutics AB's Equity-to-Asset

For the Biotechnology subindustry, Elicera Therapeutics AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elicera Therapeutics AB's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's Equity-to-Asset falls into.



Elicera Therapeutics AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Elicera Therapeutics AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=11.401/30.18
=

Elicera Therapeutics AB's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=11.401/30.18
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elicera Therapeutics AB  (OSTO:ELIC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Elicera Therapeutics AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Elicera Therapeutics AB (OSTO:ELIC) Business Description

Traded in Other Exchanges
Address
Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines